Vir Biotechnology
E446849
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
clinical-stage biopharmaceutical company ⓘ immunology company ⓘ |
| aimsTo |
address global public health threats
ⓘ
prevent infectious diseases ⓘ treat infectious diseases ⓘ |
| collaboratesWith |
GlaxoSmithKline
NERFINISHED
ⓘ
governmental health agencies ⓘ non-profit organizations ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
T cell–based therapies
ⓘ
immune-based therapies ⓘ monoclonal antibodies ⓘ prophylactics ⓘ therapeutics ⓘ |
| employs |
T cell engineering
ⓘ
antibody discovery platforms ⓘ immune modulation strategies ⓘ |
| focusesOn |
immunology
ⓘ
infectious diseases ⓘ serious infectious diseases ⓘ |
| goal |
achieve durable immune responses
ⓘ
reduce disease burden from infectious diseases ⓘ |
| hasApproach |
functional genomics
ⓘ
harnessing the immune system ⓘ machine learning–driven target identification ⓘ |
| hasPipeline |
T cell–based candidates
ⓘ
monoclonal antibody candidates ⓘ vaccinal approaches ⓘ |
| hasResearchArea |
COVID-19
NERFINISHED
ⓘ
HIV NERFINISHED ⓘ SARS-CoV-2 NERFINISHED ⓘ hepatitis B virus ⓘ influenza ⓘ malaria ⓘ tuberculosis ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| stage | clinical-stage ⓘ |
| targets |
bacterial pathogens
ⓘ
parasitic pathogens ⓘ viral pathogens ⓘ |
| therapeuticArea |
chronic viral infections
ⓘ
emerging infectious diseases ⓘ respiratory viral infections ⓘ |
| usesTechnology |
T cell technology
ⓘ
antibody technology ⓘ immune-based technology platforms ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.